BACKGROUND: The benefit of regular exercise in improving cancer outcomes is well established. The American Cancer Society (ACS) released a recommendation that cancer survivors should engage in at least 150 minutes of moderate to vigorous physical activity (PA) per week; however, few report meeting this recommendation. This study examined the patterns and correlates of meeting ACS PA recommendations in the Detroit Research on Cancer Survivors (ROCS) cohort of African American cancer survivors. METHODS: Detroit ROCS participants completed baseline and yearly follow-up surveys to update their health and health behaviors, including PA. This study examined participation in PA by select characteristics and reported health-related quality of life (HRQOL) as measured with the Functional Assessment of Cancer Therapy and Patient-Reported Outcomes Measurement Information System instruments. RESULTS: Among the first 1500 ROCS participants, 60% reported participating in regular PA, with 24% reporting ≥150 min/wk. Although there were no differences by sex, prostate cancer survivors were the most likely to report participating in regular PA, whereas lung cancer survivors were the least likely (P = .022). Survivors who reported participating in regular PA reported higher HRQOL (P < .001) and lower depression (P = .040). CONCLUSIONS: Just 24% of African American cancer survivors reported meeting the ACS guidelines for PA at the baseline, but it was encouraging to see increases in activity over time. Because of the established benefits of regular exercise observed in this study and others, identifying and reducing barriers to regular PA among African American cancer survivors are critical for improving outcomes and minimizing disparities.
BACKGROUND: The benefit of regular exercise in improving cancer outcomes is well established. The American Cancer Society (ACS) released a recommendation that cancer survivors should engage in at least 150 minutes of moderate to vigorous physical activity (PA) per week; however, few report meeting this recommendation. This study examined the patterns and correlates of meeting ACS PA recommendations in the Detroit Research on Cancer Survivors (ROCS) cohort of African American cancer survivors. METHODS: Detroit ROCS participants completed baseline and yearly follow-up surveys to update their health and health behaviors, including PA. This study examined participation in PA by select characteristics and reported health-related quality of life (HRQOL) as measured with the Functional Assessment of Cancer Therapy and Patient-Reported Outcomes Measurement Information System instruments. RESULTS: Among the first 1500 ROCS participants, 60% reported participating in regular PA, with 24% reporting ≥150 min/wk. Although there were no differences by sex, prostate cancer survivors were the most likely to report participating in regular PA, whereas lung cancer survivors were the least likely (P = .022). Survivors who reported participating in regular PA reported higher HRQOL (P < .001) and lower depression (P = .040). CONCLUSIONS: Just 24% of African American cancer survivors reported meeting the ACS guidelines for PA at the baseline, but it was encouraging to see increases in activity over time. Because of the established benefits of regular exercise observed in this study and others, identifying and reducing barriers to regular PA among African American cancer survivors are critical for improving outcomes and minimizing disparities.
Authors: Rebecca M Speck; Kerry S Courneya; Louise C Mâsse; Sue Duval; Kathryn H Schmitz Journal: J Cancer Surviv Date: 2010-01-06 Impact factor: 4.442
Authors: Caroleen W Quach; Michelle M Langer; Ronald C Chen; David Thissen; Deborah S Usinger; Marc A Emerson; Bryce B Reeve Journal: Qual Life Res Date: 2016-05-30 Impact factor: 4.147
Authors: Jan Hammarsten; Jan-Erik Damber; Mohammad A Haghsheno; Dan Mellström; Ralph Peeker Journal: Nat Rev Urol Date: 2018-02-13 Impact factor: 14.432
Authors: M A Nicolazzi; A Carnicelli; M Fuorlo; A Scaldaferri; R Masetti; R Landolfi; A M R Favuzzi Journal: Eur Rev Med Pharmacol Sci Date: 2018-04 Impact factor: 3.507
Authors: Li Tao; Scarlett Lin Gomez; Theresa H M Keegan; Allison W Kurian; Christina A Clarke Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-12 Impact factor: 4.090
Authors: Jamaica R M Robinson; Jennifer L Beebe-Dimmer; Ann G Schwartz; Julie J Ruterbusch; Tara E Baird; Stephanie S Pandolfi; Theresa A Hastert; James W Quinn; Andrew G Rundle Journal: Cancer Date: 2021-08-18 Impact factor: 6.860
Authors: Kristen S Purrington; Ann G Schwartz; Julie J Ruterbusch; Mark A Manning; Mrudula Nair; Angela S Wenzlaff; Stephanie S Pandolfi; Michael S Simon; Jennifer Beebe-Dimmer Journal: Cancer Date: 2020-08-04 Impact factor: 6.860
Authors: K Schwartz; J Beebe-Dimmer; T A Hastert; J J Ruterbusch; J Mantey; F Harper; H Thompson; S Pandolfi; A G Schwartz Journal: J Cancer Surviv Date: 2020-10-17 Impact factor: 4.062
Authors: Theresa A Hastert; Julie J Ruterbusch; Judith Abrams; Mrudula Nair; Angie S Wenzlaff; Jennifer L Beebe-Dimmer; Stephanie S Pandolfi; Ann G Schwartz Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-04-01 Impact factor: 4.090
Authors: Carly M Malburg; Juliana Fucinari; Julie J Ruterbusch; David M Ledgerwood; Jennifer L Beebe-Dimmer; Ann G Schwartz; Michele L Cote Journal: Cancer Med Date: 2020-08-21 Impact factor: 4.452
Authors: Theresa A Hastert; Jean A McDougall; Shaila M Strayhorn; Mrudula Nair; Jennifer L Beebe-Dimmer; Ann G Schwartz Journal: Cancer Date: 2020-11-23 Impact factor: 6.860
Authors: Kristen S Purrington; Sreejata Raychaudhuri; Michael S Simon; Julie Clark; Valerie Ratliff; Gregory Dyson; Douglas B Craig; Julie L Boerner; Jennifer L Beebe-Dimmer; Ann G Schwartz Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-08-31 Impact factor: 4.254
Authors: Theresa A Hastert; Anne C Kirchhoff; Matthew P Banegas; Joanna F Morales; Mrudula Nair; Jennifer L Beebe-Dimmer; Stephanie S Pandolfi; Tara E Baird; Ann G Schwartz Journal: Cancer Med Date: 2020-11-07 Impact factor: 4.452
Authors: Michael S Simon; Sreejata Raychaudhuri; Lauren M Hamel; Louis A Penner; Kendra L Schwartz; Felicity W K Harper; Hayley S Thompson; Jason C Booza; Michele Cote; Ann G Schwartz; Susan Eggly Journal: Front Oncol Date: 2021-07-07 Impact factor: 6.244